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OBJECTIVES The purpose of this study was to evaluate the safety and feasibility of endovascular cooling
during primary percutaneous coronary intervention (PCI) for acute myocardial infarction
(AMI).
BACKGROUND In experimental models of AMI, mild systemic hypothermia has been shown to reduce
metabolic demand and limit infarct size.
METHODS In a multi-center study, 42 patients with AMI (6 h from symptom onset) were randomized
to primary PCI with or without endovascular cooling (target core temperature 33°C). Cooling
was maintained for 3 h after reperfusion. Skin warming, oral buspirone, and intravenous
meperidine were used to reduce the shivering threshold. The primary end point was major
adverse cardiac events at 30 days. Infarct size at 30 days was measured using 99mTc-sestamibi
SPECT imaging.
RESULTS Endovascular cooling was performed successfully in 20 patients (95%). All achieved a core
temperature below 34°C (mean target temperature 33.2  0.9°C). The mean temperature at
reperfusion was 34.7  0.9°C. Cooling was well tolerated, with no hemodynamic instability
or increase in arrhythmia. Nine patients experienced mild episodic shivering. Major adverse
cardiac events occurred in 0% vs. 10% (p  NS) of treated versus control patients. The
median infarct size was non-significantly smaller in patients who received cooling compared
with the control group (2% vs. 8% of the left ventricle, p  0.80).
CONCLUSIONS Endovascular cooling can be performed safely as an adjunct to primary PCI for AMI. Further
clinical trials are required to determine whether induction of mild systemic hypothermia with
endovascular cooling will limit infarct size in patients undergoing reperfusion
therapy. (J Am Coll Cardiol 2002;40:1928–34) © 2002 by the American College of
Cardiology Foundation
Early and sustained reperfusion remains the only proven
method of salvaging jeopardized myocardium following
acute coronary artery occlusion (1–3). Yet, in spite of
contemporary therapies, many patients develop complica-
tions, such as congestive heart failure and death, attributable
to extensive myocardial damage. Because infarct size is one
of the most important predictors of early and late survival
after acute myocardial infarction (AMI), there is a clear
need for novel approaches to improve myocyte protection
during reperfusion therapy (4–6).
Experimental data suggest that myocardial temperature is
an important determinant of the extent of tissue necrosis
during AMI (7,8). Several studies have demonstrated that
lowering myocardial temperature even a few degrees reduces
metabolic demand and may cause a profound reduction in
infarct size, even when hypothermia is initiated after coro-
nary occlusion (7–14). The purpose of this study was to
evaluate the safety and feasibility of inducing mild systemic
hypothermia in patients with AMI undergoing primary
percutaneous coronary intervention (PCI), employing a
novel endovascular heat-exchange system.
METHODS
Study population and design. From February to July
2001, 42 patients with acute anterior or inferior myocardial
infarction were randomized to primary PCI with or without
endovascular cooling. Patients were enrolled at seven centers
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in the U.S., Australia, and Germany. All patients presented
within 6 h from symptom onset and had chest pain 30
min duration with ST-segment elevation 1 mm in two
contiguous leads. Patients with inferior AMI were required
to have 1 mm reciprocal ST-segment depression in two
precordial leads. Exclusion criteria were cardiogenic shock,
rescue angioplasty, previous AMI 1 month, Raynaud’s
disease, hypersensitivity to buspirone or meperidine, treat-
ment with a monoamine oxidase inhibitor in the previous 14
days, bleeding diathesis or coagulopathy, severe hepatic or
renal impairment, pregnancy, patient height 1.5 m, or the
presence of an inferior vena cava filter. The institutional
review board at each center approved the protocol, and all
patients provided written informed consent. Clinical
follow-up was obtained at one month.
Endovascular cooling. Endovascular cooling was initiated
either in the emergency room or in the cardiac catheteriza-
tion laboratory before primary PCI using the SetPoint
Endovascular Temperature Management System (Radiant
Medical Inc., Redwood City, California). This consists of a
proprietary triple-lobed, helically wound, heat-exchange
balloon catheter that is placed in the inferior vena cava via
the femoral vein, and a microprocessor-driven controller
that precisely alters core temperature. The catheter with the
unexpanded balloon has a 9.2F diameter and is inserted
through a 10F femoral introducer sheath until the distal tip
of the catheter is positioned at the level of the diaphragm.
The catheter is connected via insulated lines to a peripheral
cassette consisting of a pump that circulates the saline and a
thin walled heat-exchange bag that lies on a thermal transfer
plate. This cools or warms the saline circulating through the
cassette and catheter without administration of fluids to the
patient (Fig. 1).
The target core body temperature was 33°C (monitored
with a naso-esophageal probe). Cooling was maintained for
3 h after reperfusion; re-warming was then performed over
a 1 to 2 h period to 36.5°C. Shivering was suppressed using
skin warming with a forced air blanket (Bair Hugger,
Augustine Medical, Eden Prairie, Minnesota), oral buspi-
rone (30 to 60 mg), and intravenous meperidine (75 to 100
mg loading dose over 15 min, followed by an intravenous
meperidine infusion at 25 to 35 mg/h) (15).
Coronary intervention. Cardiac catheterization was per-
formed using conventional techniques and equipment. All
Abbreviations and Acronyms
AMI  acute myocardial infarction
MACE  major adverse cardiac events
PCI  percutaneous coronary intervention
TIMI  Thrombolysis In Myocardial Infarction
Figure 1. Diagram of the endovascular cooling system.
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patients received aspirin 325 mg before catheterization, and
heparin was administered during the procedure to maintain
the activated clotting time 250 s. Coronary stenting,
adjunctive thrombectomy, and use of glycoprotein receptor
inhibitors were permitted at the operator’s discretion.
Radionuclide imaging. Final infarct size was measured 30
days after primary PCI using 99mTc-sestamibi SPECT
imaging. Radionuclide images were obtained using single-
or multi-head gamma camera systems with images acquired
in a 64  64 matrix. All images were analyzed for final
infarct size by the Mayo Clinic Nuclear Core laboratory,
which was blinded to treatment assignment (16). Using a
previously reported method, the analysis pre-specified that
patients who died before final infarct size determination
were assigned values equal to the largest infarct size mea-
sured in survivors according to infarct location; those lost to
follow-up were assigned values equal to the median infarct
size in the group (17).
Study end points and definitions. The primary end point
of the study was the presence of major adverse cardiac events
(MACE) at 30 days. The secondary end point was infarct
size at 30 days, measured using 99mTc-sestamibi SPECT
imaging. Safety was also assessed through hemodynamic
and electrocardiographic monitoring as well as review of any
vascular or bleeding complications. MACE was defined as
death, non-fatal re-infarction, and ischemia-driven target
vessel revascularization. Re-infarction was defined as the
recurrence of clinical symptoms or new electrocardiographic
changes accompanied by a rise in creatine kinase-MB levels.
Data analysis. Statistical analysis was performed using
SAS software (Version 6.18, Cary, North California). Cat-
egorical variables were examined using a Pearson chi-
squared test in all cases, except as noted when a Fisher
two-sided exact test was used. Continuous variables were
examined using a Student t test. Final infarct size in each
group was compared using a Wilcoxon rank test. A p value
of 0.05 was considered statistically significant.
RESULTS
Clinical and angiographic data. Twenty-one patients
were randomized to primary PCI with endovascular cool-
ing. Clinical and angiographic characteristics are shown in
Table 1. Patients in the control group were more likely to
have hypertension (57% vs. 24%, p  0.03). Primary PCI
was performed in 41 patients (98%); one patient was
Table 1. Clinical and Angiographic Data
Cooling
(n  21)
Control
(n  21)
Age (mean  SD; range) 52  9 (39–73) 58  14 (32–83)
Women 2 (10%) 5 (24%)†
Hypertension 5 (24%) 12 (57%)*
Diabetes 4 (19%) 6 (29%)
Hyperlipidemia 9 (43%) 5 (24%)
Current smoker 14 (67%) 11 (52%)
Previous MI 3 (14%) 1 (5%)†
Previous PCI 1 (5%) 0 (0)†
Previous CABG 1 (5%) 0 (0)†
Infarct location
Anterior 9 (40%) 10 (48%)
Inferior 12 (60%) 11 (52%)
Symptom-onset to hospital arrival (min) 118  84 100  62
Door-to-balloon (min) 87  30 104  44
PCI performed 20 (95%) 21 (100%)
Peak creatine kinase 1905  1820 2030  1726
Infarct related artery
Left anterior descending artery 7 (34%) 10 (48%)
Right coronary artery 11 (52%) 10 (48%)
Circumflex artery 3 (14%) 1 (5%)
Initial TIMI flow grade‡
0/1 16 (76%) 14 (67%)
2 0 (0) 3 (14%)
3 5 (24%) 4 (19%)
Stent 15 (71%) 16 (76%)
AngioJet thrombectomy 3 (14%) 4 (19%)†
Glycoprotein IIb/IIIa inhibitor 15 (71%) 18 (86%)
TIMI flow grade post PCI‡
0/1 1 (5%) 0 (0)
2 1 (5%) 2 (10%)
3 19 (90%) 19 (90%)
*p  0.03. All other comparisons non-significant. †Fisher two-sided exact test used. ‡Core lab assessed.
CABG  coronary artery bypass grafting; MI  myocardial infarction; PCI  percutaneous coronary intervention; TIMI 
Thrombolysis In Myocardial Infarction.
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managed conservatively and later underwent repeat coronary
artery bypass graft surgery. Stenting was performed in 31
patients (74%); seven (17%) required adjunctive thrombec-
tomy. Most patients received a glycoprotein receptor inhib-
itor. A high rate of final Thrombolysis In Myocardial
Infarction (TIMI) grade flow-3 flow was achieved in both
groups.
Endovascular cooling. Baseline core temperature was
similar in each group (cooling 36.0  0.7°C vs. control 35.7
 1.2°C, p  0.58). Endovascular cooling was performed
successfully in 20 patients (95%); all achieved a core tem-
perature below 34°C (mean temperature during cooling 33.2
 0.9°C) (Fig. 2). One patient was not cooled, because of
technical problems. The mean core temperature at first
balloon inflation was 34.7  0.9°C, and the mean duration
of cooling was 241  29 min. Re-warming was performed
over 65  26 min (mean target 36.6  0.3°C). Nine
patients experienced mild episodic shivering during cooling.
Four of these were managed successfully with additional
meperidine and surface warming; five patients required a
small increase in target core temperature to between 33.5°C
and 34.2°C. The mean doses of meperidine and buspirone
administered were 177  71 mg and 51  17 mg,
respectively.
Clinical events. Endovascular cooling was well tolerated.
No hemodynamic instability was observed during cooling
(Table 2). Three patients in the cooling group and six in the
control group had a ventricular arrhythmia requiring DC
cardioversion; all patients in the cooling group were defi-
brillated without difficulty. At 30 days, MACE was ob-
served in 0% versus 10%, respectively, of treated and control
patients (p  NS) (Table 3).
Infarct size. Thirty-six patients (86%) had final infarct size
analyzed at 30 days (excluded patients had technical prob-
lems with the image [2], technical problems where cooling
was not provided per protocol [2], no primary PCI per-
formed [1], or unstable angina [1]). The median infarct size
in the cooling and control groups was 2% (90th percentile
19.0%) and 8% (90th percentile 44%) of the left ventricle,
respectively (Wilcoxon rank, p  0.80) (Fig. 3). Patients
with an occluded infarct artery at initial angiography (TIMI
grade flow 0 or 1 flow) had a larger median infarct size than
those with a patent infarct artery (8.5% vs. 0% of the left
ventricle, p  0.047).
Figure 2. Mean core body temperature in patients treated with endovascular cooling (mean  SD shown). CCU  coronary care unit.
Table 2. Hemodynamic Parameters and Respiratory Rate in Cooling and Control Groups
Baseline 1 h 2 h 3 h
Cooling Control Cooling Control Cooling Control Cooling Control
SBP 133.5  25.9 121.5  26.4 129.6  26.5 124.6  27.4 124.9  17.8 119.3  20.2 129.8  24.3 122.7  26.5*
DBP 78.8  16.0 70.1  17.2 74.4  21.7 73.6  20.6 76.3  15.7 68.3  15.9 81.7  18.0 70.6  18.0*
HR 71.4  14.2 70.1  17.2 75.9  12.7 80.3  16.5 71.2  21.6 75.7  14.7 70.5  20.1 73.3  20.0*
RR 17.2  2.5 20.4  4.5† 16.1  3.2 15.6  3.1 15.8  3.4 17.1  4.4 16.4  2.7 16.4  4.6*
*p  NS for trend (repeated measures analysis of variance). †p  0.03 for cooling vs. control. All other comparisons for cooling vs. control nonsignificant.
DBP  diastolic blood pressure (mm Hg); HR  heart rate (beats/min); RR  respiratory rate (breaths/min); SBP  systolic blood pressure (mm Hg).
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DISCUSSION
Cooling is used widely during cardio-pulmonary bypass
surgery, organ transplantation, and some neurosurgical pro-
cedures in order to limit ischemic cellular injury. Although
the focus of clinical research on therapeutic hypothermia has
been as a neuroprotective strategy, there appears to be an
equally sound rationale for the use of cooling to protect
ischemic myocardium.
Experimental studies have demonstrated an important
relationship between myocardial temperature and the extent
of tissue necrosis after coronary occlusion (7,8). Chien et al.
(7) found that infarct size changed by about 10% for each
1°C change in myocardial temperature. More recently, Dae
et al. (14) investigated the effect of mild hypothermia on
infarct size in human-sized pigs by using endovascular
cooling. Infarct size was significantly reduced in the group
treated with hypothermia (9%  6% vs. 45%  8%, p 
0.0001). Moreover, the viability results obtained by triphe-
nyltetrazolium chloride staining were confirmed by sesta-
mibi autoradiography, thus suggesting that cooling exerts a
protective effect for both myocytes and the microcirculation.
The beneficial effect of mild hypothermia appears to be
independent of hypothermia-induced bradycardia, as the
effect persists when heart rate is maintained with pacing
(7,10). One possible explanation is that hypothermia re-
duces metabolic demand in the myocardium at risk. In both
dogs and isolated perfused rabbit hearts, hypothermia has
been shown to preserve myocardial adenosine triphosphate
stores during ischemia (18,19), which may facilitate the
maintenance of cell membrane integrity. However, it is
likely that the effects of hypothermia are far more complex,
and further studies are needed to determine whether myo-
cardial cooling influences other cellular and biochemical
processes that may lead to cell death.
Despite the theoretical promise of hypothermia, two
important problems have had to be overcome to consider
implementing this strategy in AMI. First, currently avail-
able cooling techniques are impractical for the induction of
hypothermia in patients with AMI. Surface cooling using
icepacks or external cooling blankets is too slow and
cumbersome to use in AMI and also requires general
anesthesia to prevent shivering. Other methods such as
extra-corporeal blood cooling circuits, cardiopulmonary by-
pass, and peritoneal cooling allow for rapid induction of
hypothermia but are too invasive to permit widespread
application of cooling. For these reasons the introduction of
an endovascular cooling technique has been a major advance
Table 3. Clinical Events During In-Hospital Period
Cooling
(n  21)
Control
(n  21)
Death 0 2 (10%)
Re-infarction 0 0
Repeat PCI 0 2 (10%)*
CABG 1 (5%)† 0
MACE 0 2 (10%)
Stroke/TIA 0 0
Cardiogenic shock 0 2 (10%)
Pulmonary edema 1 (5%) 0
VT/VF‡ 3 (14%) 6 (29%)
Bradycardia§ 3 (14%) 4 (19%)
Transfusion 1 (5%) 0
Hematoma  6 cm 1 (5%) 0
*Nontarget vessel; †elective reoperation; ‡requiring defibrillation; §requiring insertion
of temporary venous pacemaker. p  NS for all comparisons of cooling vs. control
(Fisher two-sided exact test used).
CABG coronary artery bypass grafting; MACEmajor adverse cardiac events;
PCI  percutaneous coronary intervention; TIA  transient ischemic attack;
VT/VF  ventricular tachycardia or fibrillation
Figure 3. Final infarct size at 30 days in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction with or without
endovascular cooling (measured using 99mTc-sestamibi single photon emission computed tomography imaging). Infarct size is shown according to initial
Thrombolysis In Myocardial Infarction (TIMI) flow grade in the infarct vessel (F  assigned infarct size for patients who died; Œ  median infarct size
for group). LV  left ventricle.
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in this field. Second, a method was required to counteract
the normal thermoregulatory defenses to cooling to allow
use of hypothermia in non-ventilated patients. Numerous
drugs have been shown to reduce the threshold for shiver-
ing, but most are anesthetic agents or major sedatives and
require intensive care support with mechanical ventilation.
Recently, however the combination of meperidine and
buspirone (a 5-HT1A partial agonist) was found to syner-
gistically reduce the shivering threshold in humans without
causing respiratory depression (15). This pharmacologic
combination was therefore selected for this pilot study.
The primary purpose of this study was to evaluate the
feasibility and safety of inducing mild systemic hypothermia
in awake patients with AMI using endovascular cooling.
The results of this study suggest that: 1) mild systemic
hypothermia can be induced in patients with AMI using an
endovascular heat-exchange catheter; 2) endovascular cool-
ing is safe and well tolerated during AMI; and 3) shivering
can be suppressed successfully in awake patients during
endovascular cooling through skin warming and pharmaco-
logic therapy.
Although this is the first study to employ cooling in
AMI, the safety of mild hypothermia has been demon-
strated in several other high-risk clinical settings, including
acute ischemic stroke, traumatic brain injury and cardiac
arrest (20–25). Whereas deep hypothermia may cause
ventricular arrhythmia, coagulopathy, or immunosuppres-
sion, mild or moderate hypothermia has not been associated
with these complications. In the present study we found that
induction of mild hypothermia during AMI was well
tolerated. Although this pilot study was underpowered,
there were no unanticipated major adverse events related to
cooling. The main adverse reaction in the cooling group was
mild episodic shivering, and generally this was well con-
trolled with additional medical therapy or a small increase in
core temperature. No hemodynamic instability was seen
during cooling, and in contrast with previous studies, no
decrease in heart rate was observed.
From a technical standpoint, we found that the heat-
exchange catheter could be inserted rapidly in either the
emergency room or the catheterization laboratory, and
resulted in a rapid reduction in core temperature. All
patients treated with cooling achieved a core temperature
below 34°C, but in a small number of cases the target
temperature of 33°C was not achievable. Whether this is
related to sub-optimal heat transfer with this catheter-based
system, patient-related factors, or inadequate pharmacologic
control of shivering has yet to be established.
Conclusion. Among newer therapeutic approaches in
AMI, application of mild hypothermia has generated con-
siderable interest as a potential cardioprotective strategy.
This study demonstrated that mild systemic hypothermia
can be induced safely in patients with AMI employing a
novel heat-exchange catheter. On the basis of these prelim-
inary findings, we believe that further clinical trials are
warranted to determine whether adjunctive endovascular
cooling will limit infarct size during reperfusion therapy for
AMI.
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